Genetic marker and/or biomarkers for traumatic brain injury, and ultrasensitive assays for biomarkers of traumatic brain injury

Patent metadata

Field	Value
Publication number	US-12339275-B2
Application number	US-201916978464-A
Country	US
Kind code	B2
Filing date	Mar 8, 2019
Priority date	Mar 8, 2018
Publication date	Jun 24, 2025
Grant date	Jun 24, 2025

Abstract

The present invention relates to assays, methods, and kits to assess traumatic brain injury (TBI) in a subject. The present invention also relates to ultrasensitive assays for GFAP, tau, CKBB, IL-1β, IL-2, IL-6, IL-10, IL-22, IP-10, TNFα, TSLP, NFL, and/or NFH.

First claim

The invention claimed is:

1. An assay configured to determine or detect the presence or level of two or more biomarkers in a sample from a subject, wherein said two or more biomarkers comprise apolipoprotein 4 (APOE4) and glial fibrillary acidic protein (GFAP) and wherein said assay is configured to detect GFAP at a Lower Limit of Detection (LLOD) of 0.1 to 500 femtogram/mL.

2. The assay of claim 1 , which is configured to assess traumatic brain injury (TBI).

3. The assay of claim 1 , which is configured to determine the presence or level of APOE4 and the level of GFAP.

4. A method of assessing TBI, comprising detecting APOE4 in a subject suspected of having a traumatic brain injury.

5. The assay of claim 1 , wherein said GFAP detection is analyzed on an Meso Scale Discovery (MSD) platform.

6. The assay of claim 1 , which is configured to perform a multiplexed assay.

7. The assay of claim 1 , which is configured to be conducted in a single assay chamber.

8. The assay of claim 1 , which is configured to detect APOE4 in a sample from said subject using a nucleic acid assay.

9. The assay of claim 1 comprising, in one or more vials, containers, or compartments (a) a surface comprising (i) a capture reagent for GFAP, said capture reagent bound to the surface, and (ii) an anchoring reagent bound to an anchoring oligonucleotide sequence, said anchoring reagent bound to the surface; (b) a first detection reagent for GFAP that is linked to a first nucleic acid probe, wherein the first nucleic acid probe comprises an extended sequence that is complementary to the anchoring oligonucleotide sequence bound to the anchoring reagent; and (c) a second detection reagent for GFAP that is linked to a second nucleic acid probe; wherein the assay is combined to form a proximity-based detection system, and the assay is configured to detect GFAP at a level below 500 femtogram/mL.

10. The assay of claim 9 , wherein said assay is configured to detect GFAP at a level below 300 femtogram/mL.

11. The assay of claim 9 , wherein said assay is configured to detect GFAP at a level below 100 femtogram/mL.

12. The assay of claim 9 , wherein said assay is configured to detect GFAP at a level below 50 femtogram/mL.

13. The assay of claim 9 , wherein said assay is configured to detect GFAP at a level below 25 femtogram/mL.

14. The assay of claim 9 , wherein said assay is configured to detect GFAP at a level below 10 femtogram/mL.

15. The assay of claim 1 , wherein said APOE4 biomarker is APOE4 protein and said assay comprises an immunoassay configured to detect said APOE4 protein.

16. The assay of claim 1 , wherein said assay is two singleplex assays.

Assignees

• Meso Scale Technologies Llc
• Univ Georgetown
• Univ Texas
• Univ Texas

Inventors

• Debad Jeff
• Gatson Joshua
• Burns Mark
• Biesso Arianna

Classifications

• G01N2800/28

  Neurological disorders · CPC title

• G01N2201/0484

  Computer controlled · CPC title

• G01N35/02

  using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations {(G01N35/0098 and G01N35/0099 take precedence)} · CPC title

• G01N21/66

  electrically excited, e.g. electroluminescence · CPC title

• G01N2333/4709

  Amyloid plaque core protein · CPC title